Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2020, Vol. 40 Issue (12): 1-7    DOI: 10.13523/j.cb.2011032
新型冠状病毒检测与治疗     
重组人干扰素α1b抗新型冠状病毒的基础和临床研究进展
林福玉,刘金毅,程永庆()
北京三元基因药业股份有限公司 北京 102600
Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2
LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing()
Beijing Tri-Prime Gene Pharmaceutical Co., Ltd., Beijing 102600, China
 全文: PDF(4100 KB)   HTML
摘要：

干扰素是机体抗病毒的第一道天然防线,干扰素α1b是中国人干扰素家族中主要的抗病毒表达亚型。SARS-CoV-2通过多种途径抑制先天免疫关键分子干扰素的产生。已上市多年的重组人干扰素α1b显示出强大的体外抗SARS-CoV-2病毒活性。初步临床研究显示,包括重组人干扰素α1b在内的I型干扰素对COVID-19显示出积极的治疗和预防作用。全球多个国家正在开展干扰素治疗COVID-19的临床试验,我国自主知识产权的重组人干扰素α1b率先开展了验证性临床试验。
关键词： 新型冠状病毒;  新冠肺炎;  干扰素α1b;  治疗;  预防    
Abstract:

Interferon is the first line of innate defense against viruses infection. Interferon α1b is a major antiviral subtype of interferon family. SARS-CoV-2 have evolved several mechanisms to block interferon induction. Interferon α1b, has been approved for the antiviral clinical use for many years, showing strong in vitro antiviral activity against SARS-CoV-2. Preliminary clinical studies including type I interferon have showed critical positive efficiency on COVID-19 treatment and prevention. A clinical trial with a larger cohort of infected patients that are randomized to treatment with interferon-alpha or to a placebo is ongoing.
Key words: SARS-CoV-2    COVID-19    Interferon α1b    Treatment    Prophylaxis
收稿日期: 2020-11-17 出版日期: 2021-01-14
ZTFLH:  Q819  
通讯作者: 程永庆     E-mail: ycheng@triprime.com
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
林福玉
刘金毅
程永庆

引用本文:

林福玉,刘金毅,程永庆. 重组人干扰素α1b抗新型冠状病毒的基础和临床研究进展[J]. 中国生物工程杂志, 2020, 40(12): 1-7.

LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2. China Biotechnology, 2020, 40(12): 1-7.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2011032    或    https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I12/1

图1  三种IFN对新型冠状病毒的体外抑制浓度测定
图2  IFN各种亚型的抗SARS-CoV-2病毒活性比较
[1] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020,395(10236):1569-1578.
doi: 10.1016/S0140-6736(20)31022-9 pmid: 32423584
[2] Hernandez A V, Roman Y M, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med, 2020,173(4):287-296.
doi: 10.7326/M20-2496 pmid: 32459529
[3] Rusinova I, Forster S, Yu S, et al. INTERFEROME v2.0: an updated database of annotated interferon-regulated genes. Nucleic acids research, 2013,41(database issue):D1040-D1046.
doi: 10.1093/nar/gks1215 pmid: 23203888
[4] Hawkins M J, Borden E C, Merritt J A, et al. Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. J Clin Oncol, 1984,2(3):221-226.
doi: 10.1200/JCO.1984.2.3.221 pmid: 6321691
[5] Genin P, Vaccaro A, Cicas A. The role of differential expression of human interferon: a genes in antiviral immunity. Cytokine Growth Factor Rev, 2009,20(4):283-295.
doi: 10.1016/j.cytogfr.2009.07.005 pmid: 19651532
[6] 侯云德, 张智清, 杨新科, 等. 人白细胞干扰素基因的克隆化及其在大肠杆菌中的表达. 中国医学科学院学报, 1982,6:4-12.
Hou Y D, Zhang Z Q, Yang X K, et al. Cloning of human leukocyte interferon gene and its expression in E. coli. Acta Academiae Medicinae Sinicae, 1982,6:4-12.
[7] 侯云德. 干扰素的不同亚型与临床应用. 中国生物制品学杂志, 1993,6(4):145-148.
Hou Y D. Interferon subtype and clinical use. Chinese Journal of Biologicals, 1993,6(4):145-148.
[8] 黎孟枫, 金奇, 胡钢, 等. 一种α I型干扰素基因新变种的发现和鉴定. 中国科学(B辑), 1991,22(4):397-402.
Li M F, Jin Q, Hu G, et al. Discovery and identification of a new variant of interferon alpha I gene. Science in China (SeriesB), 1991,22(4):397-402.
[9] Chu H, Chan J F, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis, 2020,71(6):1400-1409.
doi: 10.1093/cid/ciaa410 pmid: 32270184
[10] Wölfel R, Corman V M, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020,581(7809):465-469.
pmid: 32235945
[11] Blanco-Melo D, Nilsson-Payant B E, Liu W C, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 2020,181(5):1036-1045.
doi: 10.1016/j.cell.2020.04.026 pmid: 32416070
[12] Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients. Science, 2020,369(6504):718-724.
doi: 10.1126/science.abc6027 pmid: 32661059
[13] Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol, 2020, 146(1): 206-208.e2.
doi: 10.1016/j.jaci.2020.04.029 pmid: 32360285
[14] Gordon D E, Jang G M, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets for drug-repurposing. Nature, 2020,583(7816):459-468.
doi: 10.1038/s41586-020-2286-9 pmid: 32353859
[15] Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. Cell Rep, 2020,32(12):108185.
doi: 10.1016/j.celrep.2020.108185 pmid: 32941788
[16] Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science, 2020,369(6508):1249-1255.
doi: 10.1126/science.abc8665 pmid: 32680882
[17] Mantlo E, Bukreyeva N, Maruyama J, et al. Potent antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020,179:104811.
doi: 10.1016/j.antiviral.2020.104811 pmid: 32360182
[18] Jiang R M, Han B, Song M H, et al. Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial. J Inflamm (Lond), 2020,17:19. DOI: 10.1186/s12950-020-00249-1.
doi: 10.1186/s12950-020-00249-1
[19] Hung I F, Lung K C, Tso E Y, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020,395(10238):1695-1704.
doi: 10.1016/S0140-6736(20)31042-4 pmid: 32401715
[20] Gemcioglu E, Davutoglu M, Ozdemir E E, et al. Are type 1 interferons treatment in multiple sclerosis as a potential therapy against COVID-19? Multi Scler Relat Dis, 2020,42:102196.
[21] Zhou Q, Chen V, Shannon C P, et al. Interferon-α2b treatment for COVID-19. Front Immunol, 2020,11:1061.
doi: 10.3389/fimmu.2020.01061 pmid: 32574262
[22] Shen K L, Yang Y H, Wang T Y, et al. Diagnosis, treatmnet, and prevention of 2019 novel cornavirus in children: experts’ consensus statement. World J Pediatr, 2020. DOI: 10.1007/s12519-020-00343-7.
doi: 10.1007/s12519-020-00343-7 pmid: 32578007
[23] 陈军, 刘丹萍, 刘莉, 等. 硫酸羟氯喹治疗冠状病毒病(COVID-19)普通型患者的初步研究. 浙江大学学报(医学版), 2020,49(2):215-219.
Chen J, Liu D P, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci), 2020,49(2):215-219.
[24] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020,368:m1091.
doi: 10.1136/bmj.m1091 pmid: 32217556
[25] Mary A, Hénaut L, Schmit J L, et al. Therapeutic options for coronavirus disease 2019 (COVID-19) -modulation of type I interferon response as a promising strategy? Front Public Health, 2020,8:185.
doi: 10.3389/fpubh.2020.00185 pmid: 32574289
[26] Yamagata Y, Yuasa Y, Yamamoto K, et al. Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver. J Interferon Cytokin Res, 2000,20(2):153-160.
[27] Hou Y J, Okuda K, Edwards C E, et al. SARS-CoV-2 Reverse genetics reveals a variable infection gradient in the respiratory tract. Cell, 2020,182(2): 429-446.e14.
doi: 10.1016/j.cell.2020.05.038 pmid: 32526205
[28] Meng Z J, Wang T Y, Chen L, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv, 2020,7. DOI: doi.org/10.1101/2020.04.11.20061473.
doi: doi.org/10.1101/2020.04.11.20061473
[29] Sallard E, Lescure F X, YazdanYazdanpanah F M, et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res, 2020,178:104791.
doi: 10.1016/j.antiviral.2020.104791 pmid: 32275914
[30] 程永庆, 刘金毅, 林福玉, 等. 重组人干扰素α1b与新型冠状病毒肺炎防治. 中国生物工程杂志, 2020,40(1-2):71-77.
Cheng Y Q, Liu J Y, Lin F Y, et al. Novel coronavirus control and the important contribution of interferon α1b. China Biotechnology, 2020,40(1-2):71-77.
[1] 赵晓煜,徐祺玲,赵晓东,安云飞. 基因治疗慢病毒载体的转导增强策略*[J]. 中国生物工程杂志, 2021, 41(8): 52-58.
[2] 贠涛,巩玥,谷芃,徐冰冰,李瑾,赵洗尘. 中国与“一带一路”参与国家抗击新冠肺炎疫情的国际科技合作现状与展望[J]. 中国生物工程杂志, 2021, 41(7): 110-121.
[3] 许叶春,柳红,李剑峰,沈敬山,蒋华良. 抗新冠肺炎药物研究进展[J]. 中国生物工程杂志, 2021, 41(6): 111-118.
[4] 史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[5] 张赛,王刚,刘仲明,李辉军,汪大明,钱纯亘. 新型冠状病毒胶体金抗原快速检测试剂的研制及性能评价*[J]. 中国生物工程杂志, 2021, 41(5): 27-34.
[6] 吕慧中,赵晨辰,朱链,许娜. 外泌体靶向递药在肿瘤治疗中的进展[J]. 中国生物工程杂志, 2021, 41(5): 79-86.
[7] 范月蕾,王跃,王恒哲,李丹丹,毛开云. 新型冠状病毒体外诊断技术研发现状与展望 *[J]. 中国生物工程杂志, 2021, 41(2/3): 150-161.
[8] 原博,王杰文,康广博,黄鹤. 双特异性纳米抗体的研究进展及其应用 *[J]. 中国生物工程杂志, 2021, 41(2/3): 78-88.
[9] 傅桂娥,李瑾,耿佩然,申梦秋,张金倩楠,赵洗尘. 医疗视角下粤港澳大湾区典型城市的新冠肺炎(COVID-19)疫情防控力量比较研究*[J]. 中国生物工程杂志, 2021, 41(12): 125-140.
[10] 唐德平,邢梦洁,宋文涛,姚慧慧,毛爱红. microRNA治疗在癌症及其他疾病中的研究进展*[J]. 中国生物工程杂志, 2021, 41(11): 64-73.
[11] 吴忧,辛林. 新的药物传递系统:外泌体作为药物载体递送*[J]. 中国生物工程杂志, 2020, 40(9): 28-35.
[12] 张赛,向乐,李林海,李辉军,王刚,钱纯亘. 新型冠状病毒(2019-nCoV)IgM /IgG抗体检测试剂的研制及性能评价[J]. 中国生物工程杂志, 2020, 40(8): 1-9.
[13] 毛开云,赵若春,王跃,范月蕾,江洪波. 全球细胞治疗CMO/CDMO行业发展态势分析 *[J]. 中国生物工程杂志, 2020, 40(6): 106-112.
[14] 武瑞君,李治非,张鑫,濮润,敖翼,孙燕荣. 新冠病毒抗体药物研发进展及展望分析[J]. 中国生物工程杂志, 2020, 40(5): 1-6.
[15] 李玉,张晓. 日本细胞治疗监管双轨制的经验及启示 *[J]. 中国生物工程杂志, 2020, 40(1-2): 174-179.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会